Taiwan Continuous Glucose Monitoring (CGM) Market - Strategic Insights and Forecasts (2026-2031)

The Taiwan Continuous Glucose Monitoring (CGM) market is forecast for significant expansion, growing at a CAGR of 20.7% from 2026 to 2031. The market is projected to reach USD 27.1 million in 2031, up from USD 10.6 million in 2026. This upward trajectory is primarily driven by factors such as the increasing prevalence of diabetes and a heightened awareness of CGM technology.

Key drivers for the Taiwan CGM market include the growing prevalence of diabetes, with the number of affected individuals aged 20-79 projected to reach 2,979.4 thousand by 2030. Additionally, heightened awareness and acceptance of CGM technology, robust government support and policy initiatives, increasing disposable income, and a growing focus on healthcare contribute significantly to the market's expansion.

In Taiwan, companies such as Bionime are making significant strides in the CGM market. A notable development includes Bionime Corporation receiving approval from the TFDA (Taiwan FDA) in October 2023 for its iFree Continuous Glucose Monitoring System (iFree CGM). This system is designed for detecting glycemic trends and managing glucose levels, benefiting both diabetes patients and those needing general glucose management.

While primarily serving individuals with Type 1 and Type 2 diabetes, the iFree Continuous Glucose Monitoring System (iFree CGM) approved in Taiwan is also noted to benefit people who need it for general glucose management, beyond a specific diabetes diagnosis. Moreover, CGM devices play a pivotal role in empowering 'remote' patients by enabling continuous monitoring and data transmission, facilitating timely interventions and potentially reducing hospital visits.

The rising prevalence of diabetes and impaired glucose tolerance (IGT) is a critical factor poised to drive immense growth in the Taiwan CGM market. The number of individuals aged 20-79 with diabetes is projected to escalate to 2,979.4 thousand by 2030, while the age-adjusted comparative prevalence of IGT is estimated to reach 12.4% by 2030. This increasing patient pool underscores the imperative for sustained expansion and enhanced diabetes management through CGM technologies.

Robust government support and policy initiatives are identified as key drivers contributing to the significant growth of the Taiwan CGM market. These initiatives foster a favorable environment for the adoption and acceptance of CGM technology. Such backing is crucial for transforming patient care and enhancing diabetes management for thousands of individuals across Taiwan, ensuring market growth and sustained expansion.